Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kae Leopoldo has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Alcohol Consumption Patterns and Chronic Pain: Findings From the 2019 Brazilian National Health Survey

    by Mariana Campello de Oliveira, Maria Olivia Pozzolo Pedro, Kae Leopoldo, Douglas Henrique Crispim, João Maurício Castaldelli‐Maia

    Introduction: Chronic pain and harmful alcohol use are prevalent and disabling conditions with shared neurobiological and social determinants, yet their relationship remains understudied in low‐ and middle‐income countries. Methods: Cross‐sectional data from 90,846 adults with complete data on the 2019 Brazilian National Health Survey were analysed. Chronic pain was categorised as back pain, rheumatism/arthritis and repetitive strain injury/work‐related musculoskeletal disorder. Alcohol use was assessed by consumption frequency (six categories), binge drinking and average daily intake. Weighted logistic regression models adjusted for sociodemographic and clinical variables were applied. Results: A U‐shaped association was observed between alcohol consumption frequency and chronic pain: compared with regular‐high frequency drinkers (3–5 days/week, reference), higher odds of chronic pain were observed among near‐daily (odds ratio [OR] 1.73; 95% confidence interval [CI] 1.17–2.56), occasional (OR 1.61; 95% CI 1.20–2.15), infrequent (OR 1.42; 95% CI 1.11–1.82) and regular‐low (1–2 days/week; OR 1.28; 95% CI 1.03–1.60) drinkers. Binge drinking was independently associated with higher odds of chronic pain (OR 1.21; 95% CI 1.03–1.42). Female sex (OR 1.65; 95% CI 1.49–1.83) and depression (OR 2.67; CI 2.32–3.07) showed strong associations with chronic pain. Alcohol quantity (g/day) was not significantly associated with chronic pain in sensitivity analyses. Discussion and Conclusions: Frequent alcohol use, binge drinking, female sex and depression were independently associated with chronic pain in this low‐ and middle‐income countries population. These associations highlight the importance of addressing behavioural and mental health patterns in pain management. Future longitudinal studies are needed to determine the directionality of these associations.

  • Open Access

    Substance Abuse as a Window into Executive Functioning: Real-World Insights for the Second Wave of Executive Function Research

    by Paulo G. Laurence, Kae Leopoldo

    Executive function (EF) research is undergoing a “second wave,” shifting from decontextualized skills to contextually embedded processes shaped by culture, habits, and social practices. While developmental studies highlight this variability, open questions remain about whether EF is entirely context-specific or grounded in shared mechanisms. Substance abuse research offers crucial insights. Decades of evidence show that environmental changes—such as reducing exposure to cues or restructuring social contexts—can alter EF-related behaviors, underscoring the central role of context. At the same time, the high comorbidity across substances points to a common inhibitory substrate, suggesting that EF is both general and context-sensitive. Addiction thus provides a uniquely real-world laboratory for examining executive processes, revealing how regulation unfolds in consequential settings where failures or successes carry immediate costs. Integrating these insights advances EF theory toward models that are both ecologically valid and theoretically rigorous.

  • Open Access

    Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review of Pharmacological Effects, Adverse Outcomes, and Therapeutic Potentials

    by Paula S. C. C. Castro, Kae Leopoldo, Maria Olivia Pozzolo Pedro, Juliana Takitane, Henrique Silva Bombana, André Brooking Negrão, Jaqueline R. Scholz, João Maurício Castaldelli-Maia

    Objective: To systematically review the scientific literature on lysergic acid amide (LSA), focusing on its physical, neurobiological, and social effects, as well as its potential risks and therapeutic uses. Methods: A systematic review was conducted across PubMed, Google Scholar, and Web of Science up to December 2023, using keywords such as “ergine,” “lysergic acid amide,” and “legal high.” Studies were included if they reported original human data on the physical, neurobiological, psychological, or social effects of LSA; seventeen studies were included. Animal studies, in vitro research, and non-original articles were excluded. Two independent reviewers screened and selected the studies, with a third resolving discrepancies. Data were extracted using a standardized form. The review followed PRISMA guidelines and was prospectively registered on the Open Science Framework. Results: LSA is primarily consumed through preparations made from the seeds of Convolvulaceae plants. Reported effects include euphoria, hallucinations, nausea, and anxiety. Severe adverse outcomes, such as psychosis, hypertension, and hospitalization, have also been documented. Some evidence suggests its potential therapeutic application for cluster headaches. However, variability in dosing and misinformation on digital platforms heighten the risks associated with LSA use. Conclusions: LSA poses significant health risks, exacerbated by online misinformation and variability in its effects, and a lack of scientific studies. Further research is essential to clarify its pharmacological profile, establish guidelines for safe use, and raise public awareness about its dangers.


  • Open Access

    Psychiatric Comorbidities Associated with Food Addiction in Post-Bariatric Patients: Toward Personalized Mental Health Screening and Postoperative Care

    by Ligia Florio, Maria Olivia Pozzolo Pedro, Kae Leopoldo, Maria Amalia Accari Pedrosa, João Mauricio Castaldelli-Maia

    Background: Food addiction (FA) is an emerging construct that mirrors the behavioral and neurobiological characteristics of substance use disorders. Despite growing interest, its association with specific psychiatric disorders among bariatric patients remains understudied. Objective: Our aim was to examine the prevalence and strength of associations between FA and seven major psychiatric disorders in individuals who underwent bariatric surgery. Methods: In a sample of 100 post-bariatric patients referred for psychiatric evaluation, FA was assessed using the modified Yale Food Addiction Scale 2.0 (mYFAS 2.0), and psychiatric disorders were diagnosed using the Mini International Neuropsychiatric Interview (MINI). Logistic regression models were used to estimate adjusted odds ratios (aORs) for the association between FA and each psychiatric disorder, controlling for sex, age, body mass index (BMI), employment status, the number of children, clinical comorbidities, physical activity, family psychiatric history, and region of residence. Results: FA was present in 51% of the sample. Descriptive analyses revealed a significantly higher prevalence of major depressive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, agoraphobia, obsessive–compulsive disorder, and bulimia nervosa among individuals with FA. Multivariate models showed robust associations between FA and bulimia nervosa (aOR = 19.42, p < 0.05), generalized anxiety disorder (aOR = 2.88, p < 0.05), obsessive–compulsive disorder (aOR = 6.64, p < 0.05), agoraphobia (aOR = 3.14, p < 0.05), social anxiety disorder (aOR = 4.28, p < 0.05) and major depressive disorder (aOR = 2.79, p < 0.05). Conclusions: FA is strongly associated with a range of psychiatric comorbidities in post-bariatric patients, reinforcing the need for comprehensive mental health screening in this population. These findings underscore the potential role of FA as a clinical marker for stratified risk assessment, supporting more personalized approaches to mental health monitoring and intervention following bariatric surgery.

  • Open Access

    Combination of Drugs in the Treatment of Alcohol Use Disorder: A Meta-Analysis and Meta-Regression Study

    by João Vitor Guimarães Mandaji, Maria Olivia Pozzolo Pedro, Kae Leopoldo, João Pini Alemar, Julio Torales, Antonio Ventriglio, João Mauricio Castaldelli-Maia

    Background: Alcohol Use Disorder (AUD) is highly prevalent among substance use disorders worldwide and is characterized by a multifactorial pathophysiology. AUD treatment is mostly based on combined pharmacotherapy and multidisciplinary clinical approaches. Nonetheless, meta-analytical studies assessing the efficacy of combination therapy are scarcely available. Methods: We searched for randomized clinical trials through PubMed, ClinicalTrials.gov, Cochrane Library, SciELO, Biblioteca Virtual em Saúde, and Google Scholar databases. Original clinical trials published in English and Portuguese were selected. Data collection followed the PRISMA and MOOSE guidelines and was assessed using the Risk of Bias Tool (RoB 2). Heterogeneity was assessed using the Q test. Meta-regression was conducted using Egger’s regression method. Twelve articles were finally included in the analysis, and random-effects models were applied on aggregate trial results. Results: The meta-analysis found that combination therapies led to an average 4.045% increase in abstinence rates (95% CI: 0.415% to 7.675%) compared to monotherapies. Meta-regression showed a strong positive association between the use of naltrexone, acamprosate, and sertraline—either alone or in combination—and treatment success in AUD. The meta-regression also highlighted the impact of patients’ variables, such as gender, age, country, and psychiatric comorbidities, on their treatment outcomes. These findings may identify a potential therapeutic pathway promoting alcohol abstinence, further supported by a Number Needed to Treat (NNT) of 25, as an acceptable value for substance use disorder treatments. Conclusions: Combined pharmacotherapies are more effective than monotherapy in enhancing abstinence rates in AUD treatment, with naltrexone, acamprosate, and sertraline emerging as key adjunctive agents promoting these outcomes. These findings underscore the complexity of AUD as a multifactorial psychiatric condition and highlight the potential of combined pharmacotherapy as a promising strategy for achieving better treatment outcomes, particularly in terms of abstinence rates.


  • Open Access

    Exploring the Practice of Dual Vaping: Health Risks and Behavioral Patterns in Nicotine and Cannabis E-Cigarette Users

    by Giovanna Nelda Vaccari Bongetta, Raony Ferreira França, Maria Olivia Pozzolo Pedro, Kae Leopoldo, Luiza Larrubia Alvares Florence, Israel Kanaan Blaas, Gislaine Koch Gimenes, Julio Torales, Antonio Ventriglio, Domenico de Berardis, et al.

    Background: E-cigarettes, initially designed for nicotine consumption, are now increasingly being used to smoke cannabis, resulting in a growing trend known as “dual vaping”. This term describes individuals, referred to as “dual users”, who use e-cigarettes for both substances. This study aims to review and analyze existing research on dual vaping, with a focus on the associated health risks and behavioral patterns. Methods: A narrative review of the literature was conducted using PubMed. Studies focusing on individuals who use electronic cigarettes for vaping tobacco and cannabis, either chronically or episodically, were examined. Relevant articles were identified and thematically synthesized to provide a comprehensive overview of the topic. Results: Dual vaping was found to be prevalent among younger men, White and Hispanic populations, and individuals with higher economic status and educational level. The use of one substance was shown to predispose individuals to the use of the other, often leading to concurrent use of both substances. Peer influence and positive expectations regarding e-cigarettes were identified as significant predictors of dual use. Dual vapers exhibited a higher susceptibility to respiratory and systemic symptoms compared to those who exclusively vaped nicotine or cannabis. Moreover, a notable prevalence of psychiatric disorders, such as substance use disorders, anxiety, and depression, was observed in this group. Fruit-flavored e-cigarettes were the most preferred option among dual vapers when using both nicotine and cannabis. Conclusions: Current evidence is insufficient to fully elucidate the long-term impacts of dual vaping on physical and mental health, particularly when compared to individuals who have never vaped. Further studies are needed to gain a more comprehensive understanding of this behavior.


  • Open Access

    Exploring the Practice of Dual Vaping: Health Risks and Behavioral Patterns in Nicotine and Cannabis E-Cigarette Users

    by Giovanna Nelda Vaccari Bongetta, Raony Ferreira França, Maria Olivia Pozzolo Pedro, Kae Leopoldo, Luiza Larrubia Alvares Florence, Israel K. Blaas, Gislaine Koch Gimenes, Julio Torales, Antonio Ventriglio, Domenico De Berardis, et al.

    Background: E-cigarettes, initially designed for nicotine consumption, are now increasingly being used to smoke cannabis, resulting in a growing trend known as "dual vaping." This term describes individuals, referred to as "dual users," who use e-cigarettes for both substances. This study aims to review and analyse existing research on dual vaping, with a focus on the associated health risks and behavioral patterns. Methods: A systematic search on PubMed was performed up to August 2023. Studies investigating individuals who use electronic cigarettes for vaping tobacco and cannabis, either chronically or episodically, were included. Articles that met the inclusion criteria were thoroughly reviewed and analysed. Results: A total of 1,778 studies were screened, of which 53 articles were reviewed, and 25 met the inclusion criteria. Four main characteristics emerged: the demographic variables of users, their health risks, behaviours, and predisposing factors to smoking. Dual Vaping was found to be prevalent among younger men, White and Hispanic populations, and individuals with higher economic status and educational level. The use of one substance was shown to predispose individuals to the use of the other, often leading to concurrent use of both substances. Peer influence and positive expectations regarding e-cigarettes were identified as significant predictors of dual use. Dual Vapers exhibited a higher susceptibility to respiratory and systemic symptoms compared to those who exclusively vaped nicotine or cannabis. Moreover, a notable prevalence of psychiatric disorders, such as substance use disorders, anxiety, and depression, was observed in this group. Fruit-flavored e-cigarettes were the most preferred option among Dual Vapers when using both nicotine and cannabis. Conclusion: Current evidence is insufficient to fully elucidate the long-term impacts of dual vaping on physical and mental health, particularly when compared to individuals who have never vaped. Further studies are needed to gain a more comprehensive understanding of this behaviour.

  • Neurobiological associations between smoking and internalizing disorders

    by Tomás Mouro Ferraz Lima, João Mauricio Castaldelli-Maia, Gisèle Apter, Kae Leopoldo

    People with severe mental disorders have a higher mortality rate due to preventable conditions like cardiovascular diseases and respiratory diseases. Nicotine addiction is a preventable risk factor, with tobacco use being twice as high in people with mental disorders. An integrative model that divides mental disorders into externalising, internalising, and thought disorders could be useful for identifying common causalities and risk factors. This review aims to examine the interface between smoking and internalising disorders, specifically schizophrenia, depressive disorders, and anxiety disorders. The review finds that there is a clear association between smoking behaviour and these disorders. Schizophrenia is associated with polymorphisms that result in an imbalance between glutamate and GABA release and abnormalities of dopaminergic pathways. Nicotine improves dopaminergic signalling and balances glutamatergic and GABAergic pathways, improving symptoms and increasing the risk of nicotine dependence. In depressive disorders, smoking is associated with functional changes in brain regions affected by smoking and self-medication. In anxiety disorders, there is a bidirectional relationship with smoking, involving the amygdala and changes in dopaminergic pathways and cortisol production. Smoking poses a threat to people living with psychiatric disorders and calls for further research to assess the interactions between nicotine dependence and internalising and thought disorders.


  • Open Access

    Pharmacological Treatment of Alcohol Cravings

    by Matheus Cheibub David Marin, Maria Olívia Pozzolo Pedro, Giuliana Perrotte, Anderson S. Martins-Da-Silva, Dangela L. S. Lassi, Israel Kanaan Blaas, Fernando Ikeda Castaldelli, Maria Beatriz Brisola dos Santos, Guilherme Trevizan Kortas, Marcela Waisman Campos, et al.

    (1) Background: The treatment of substance addiction is challenging and has persisted for decades, with only a few therapeutic options. Although there are some recommendations for specific treatments for Alcohol Use Disorder (AUD), there is no specific medication used to treat alcohol cravings, which could benefit millions of patients that are suffering from alcoholism. Cravings, or the urge to use drugs, refer to the desire to experience the effects of a previously experienced psychoactive substance. (2) Methods: We included original studies of alcohol abuse or dependence extracted from a controlled, blind, pharmacological treatment study which presented measures and outcomes related to alcohol cravings. (3) Results: Specific drugs used for the treatment of alcoholism, such as Naltrexone and Acamprosate, have had the best results in relieving craving symptoms, as well as promoting abstinence. Baclofen and anticonvulsants such as Gabapentin and Topiramate have shown good results in promoting abstinence and the cessation of cravings. (4) Conclusions: Specific drugs used for the treatment of alcoholism to obtain the best results can be considered the gold standard for promoting abstinence and relieving cravings. Anticonvulsants and Baclofen also had good results, with these medications being considered as second-line ones. Varenicline is an option for alcohol dependents who also concomitantly ingest tobacco.


  • Treating drug disorders with virtual reality: Are we there yet?

    by Kae Leopoldo, Joao Mauricio Castaldelli-Maia